HRS-2129 for Acute Gouty Arthritis: Quick Safety and Dosing Check
Official title: Clinical Study on Safety and Efficacy of HRS-2129 for Acute Gouty Arthritis
Run by Shandong Suncadia Medicine Co., Ltd. · NCT07706777 · Data updated 2026-11-12
A Phase 2 trial tests whether HRS-2129 tablets, at different doses, are safe and helpful for people with acute gouty arthritis.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Shandong Suncadia Medicine Co., Ltd. Industry-sponsored |
| Locations | 2 sites (Guangzhou, Guangdong and 1 other locations) |
| Status | Recruiting |
| Started | August 19, 2026 |
| Main results expected | October 2026 |
| Study ends | November 2026 |
| Registry record updated | September 3, 2026 |
| Trial ID | NCT07706777 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with acute gouty arthritis experiencing a target joint pain of 50 mm or higher who can provide informed consent and meet safety criteria.
✕Probably not a fit
Participants with significant liver/kidney dysfunction, certain cardiac conditions, or other disqualifying factors may not benefit from the treatment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional Phase 2 study evaluates the safety and potential efficacy of HRS-2129 in adults with acute gouty arthritis. Participants receive either HRS-2129 tablets at different dose levels or placebo to identify a reasonable dosage and examine initial signals of benefit. Key eligibility requires a target joint pain score of at least 50 mm on screening and informed consent. Exclusions include significant allergies, nervous system or mental health issues, abnormal liver or kidney function, uncontrolled hypertension, certain cardiac conditions, and other factors deemed unsuitable by investigators. The trial is led by Shandong Suncadia Medicine Co., with sites in Guangzhou and Nanjing, and involves no listed collaborators.
Why it matters
Potential benefit: If successful, participants may experience reduced pain and faster improvement during an acute gout flare.
How similar studies have gone: There is limited public information on prior studies of HRS-2129 for this condition; the approach appears exploratory for this indication, with some precedent in phase II testing of targeted therapies for gout.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Able and willing to provide a written informed consent 2. Subjects requiring Acute gouty arthritis 3. Target joint VAS pain score ≥ 50 mm (screening) Exclusion Criteria: 1. Subjects with a history of severe allergies 2. Subjects with nervous system disease 3. Subjects with a history of mental illness 4. Subjects with abnormal liver and renal function 5. Subjects with poorly controlled hypertensive 6. QTc：\>450ms（male），\>470ms（female） 7. History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s) 8. The investigators determined that other conditions were inappropriate for participation in this clinical trial
Where it's running
-
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China Recruiting -
Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China Recruiting
Study contacts
- Study coordinator: Lei Tang
- Email: lei.tang.lt31@hengrui.com
- Phone: +0518-82342973
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Plonmarlimab treatment for acute gouty arthritis
This trial will test whether plonmarlimab can reduce pain and other symptoms in adults having acute gout attacks who cannot use or did not respond to colchicine or NSAIDs.
-
HRS-1780 for people with uncontrolled or resistant high blood pressure
This trial tests whether HRS-1780 can safely help adults with uncontrolled or resistant hypertension.
-
Safety test of HRS-7156 in healthy adults
This study tests whether HRS-7156 is safe and tolerated in healthy adults aged 18–55.
-
KRAS G12C pancreatic cancer: a single-arm study of HRS-7058
This study tests whether the KRAS G12C inhibitor HRS-7058 can help adults with advanced pancreatic cancer who have already tried other treatments.
-
Blood pressure medicine HRS-7535 tested in adults with hypertension and overweight/obesity
This study tests whether HRS-7535 lowers blood pressure better than placebo in adults with hypertension who are overweight or obese.
-
HRS-1780 to slow kidney function decline in people with chronic kidney disease
We will test whether daily HRS-1780 tablets can slow kidney function decline compared with placebo in adults with chronic kidney disease who are on standard treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.